Implementation of an Antimicrobial Stewardship Program in the Vascular Surgery Ward of a university tertiary care hospital in Pavia, Northern Italy

doi:10.21203/rs.3.rs-1636035/v3

Download PDF

Research Article

Implementation of an Antimicrobial Stewardship Program in the Vascular Surgery Ward of a university tertiary care hospital in Pavia, Northern Italy

https://doi.org/10.21203/rs.3.rs-1636035/v3

This work is licensed under a CC BY 4.0 License

Journal Publication

published 06 Mar, 2023

Read the published version in BMC Infectious Diseases →

You are reading this latest preprint version

Purpose. The commitment of multidisciplinary teams in antimicrobial stewardship programs (ASPs) is often inadequately considered, especially in surgical wards. We wanted to evaluate clinical, microbiological, and pharmacological outcomes before and after the implementation of an ASP in the Vascular Surgery ward of Fondazione IRCCS Policlinico San Matteo, a tertiary care hospital in Pavia, Italy.

Methods. This was a quasi-experimental quality-improvement study. The antimicrobial stewardship activity was conducted twice a week for 12 months and consisted of both prospective audit and feedback of all the ongoing antimicrobial prescriptions by the infectious diseases’ consultants and educational meetings for the healthcare workers of the Vascular Surgery ward. For comparison between the study periods, Student t test (Mann-Whitney test for skewed distributions) was used for quantitative variables (ANOVA or Kruskall-Wallis for >2 groups respectively), and Pearson’s chi-squared test (Fisher exact test where appropriate) for categorical variables. 2-tailed tests were used. P-value significance cut-off was 0.05.

Results. During the 12-month intervention period, among a total number of 689 patients, 186 prescriptions were revised, mostly leading to de-escalating an ongoing antimicrobial therapy (39, 20.97%). A statistically significant reduction in isolates of carbapenem-resistant Pseudomonas aeruginosa (p-value 0.003) and the absence of Clostridioides difficileinfections were reported. No statistically significant changes were observed in terms of length of stay and all-cause in-hospital mortality. A significant decrease in the administration of carbapenems (p-value 0.01), daptomycin (p-value <0.01) and linezolid (p-value 0.43) was registered. A significant reduction in antimicrobial costs was also observed.

Conclusions. The implementation of a 12-month ASP brought significant clinical and economic results, highlighting the benefits of a multidisciplinary teamwork.

vascular surgery

antimicrobial stewardship program

multidisciplinary team

It has currently become a commonly accepted wisdom that antimicrobial resistance (AMR) is a major threat to global health [1], and infections caused by multidrug resistant organisms (MDRO) are undoubtedly associated with increased morbidity, mortality and healthcare costs [2] [3]. Hence, since the causal role of antimicrobial use in the development of antimicrobial resistance is not questionable [4], antimicrobial stewardship programs (ASPs), aimed at optimizing antimicrobial consumption, are increasingly in demand.

However, a key point which appears to be as essential as rarely stressed, is the extent of multidisciplinary teams in achieving these interventions [5]. This means that it is not the infectious diseases (ID) specialist who merely imparts an over specific expertise; rather, the multidisciplinary stewardship team would include other specialists, who may take the occasion to become more aware of the AMR threat and consequently keen to improve the management of antimicrobial drugs in their wards of competence.

This topic applies not only to clinical wards, but also and especially to surgical ones, as for some of the most common surgical conditions an infectious aetiology can be recognized [6]. Particularly in the Vascular Surgery ward, patients with chronic peripheral artery disease (PAD), often associated with insufficient glycaemic control and neuropathy are at increased risk of acquiring MDRO infections, thus frequently needing multiple antibiotic treatments [7]; moreover, surgical procedures expose them to surgical site infections.

With this in mind, we hereby sought to firstly evaluate how the implementation of an ASP based on a multidisciplinary team impacted on the occurrence of MDRO infections in the Vascular Surgery ward of our tertiary care hospital in Pavia, Northern Italy. Secondly, we evaluated how this ASP affected some hospital indicators of healthcare quality, such as the mean length of stay (LOS), the all-cause in-hospital mortality rate, the antimicrobial consumption, and the costs. Specifically, we selected readily recognisable measures, that are not only straightforward to evaluate before, during and after the intervention, but more importantly, potentially feasible for all surgical and non-surgical wards.

Study design, settings, and duration

This quasi-experimental quality-improvement study was applied in the Vascular Surgery ward of Fondazione IRCCS Policlinico San Matteo, a tertiary care hospital in Pavia, Italy.

The study was conceived and designed according to the SQUIRE 2.0 guidelines [8], with the aim to evaluate clinical, microbiological, and pharmacological outcomes by comparing a 12-month baseline period prior to the implementation of the ASP (Period A) to a 12-month period following its start (Period B). Specifically, Period A covered from the 1st July 2017 to the 30th June 2018, while Period B ranged from the 1st July 2018 to the 30th June 2019.

Data related to Period A for comparison were retrospectively collected from the hospital digital data warehouse, clinical records, and discharge letters. The monthly antibiotic and antifungal consumptions were inferred from the dispensation from the hospital pharmacy to the Vascular Surgery ward and converted in Defined Daily Dose (DDDs) per 100 patient days (PDs), according to the WHO definition.

Intervention

Our antimicrobial stewardship intervention was based on the presence of at least two ID consultants in the Vascular Surgery ward twice a week (on Monday and Thursday afternoons) for about two hours per day and was continued for a 12-month period (Period B). It included two types of enabling elements:

Prospective audit and feedback. For every patient hospitalised for at least 48 hours and receiving at least one antibiotic and/or antifungal drug during the intervention activity, a revision of the antimicrobial prescription was conducted through an active discussion among the two ID consultants and a resident or a senior surgeon, resulting in a written consultation included in the medical record of the patient. Each evaluation considered the clinical picture, blood tests, radiological exams and microbiological results. Decisions on the prescriptions were coded as follows: Antimicrobials not recommended; Stop antimicrobials; De-escalate antimicrobials (by switching from parenteral to oral, narrowing the spectrum of activity or reducing the number of drugs administered); Change antimicrobials; Change dosage of antimicrobials; Continue antimicrobials; Start antimicrobials; Escalate antimicrobials (by switching from oral to parenteral, broadening the spectrum of activity, increasing the number of drugs administered).

Educational meetings about antimicrobial stewardship and infection control. During Period B, monthly meetings were organized by the ID consultants to increase knowledge about AMR, hospital-acquired infections and infection control. Particularly, the consultants showed both medical and non-medical healthcare workers staff (i.e., nurses and auxiliary staff) the basic principles of patient contact isolation, cohorting, hand hygiene and the use of personal protection equipment (PPE) in case of patients either colonized or infected with MDRO or Clostridioides difficile.

Measures

The primary outcome of the study was to evaluate the impact of the implementation of an ASP in the Vascular Surgery ward on the occurrence of MDRO infections.

Secondary outcomes included changes before, during and after the implementation of the ASP in terms of length of stay (LOS), all-cause in-hospital mortality rate, antimicrobial consumption, and costs.

Definitions

Definitions used in the paper and codes for the types of infections diagnosed in the Vascular Surgery ward during the study period are summarized in Table 1.

Table 1

Summary of definitions used.
Definition		References and guidelines
Acute bacterial skin and skin structure infection (ABSSSI) and/or Surgical site infection (SSI)	ABSSSI: A bacterial infection of the skin with a lesion size area of at least 75cm² (lesion size measured by the area of redness, oedema and induration). SSI: An infection related to a surgical procedure that occurs near the surgical site within 30 days following surgery (or up to 90 days following surgery where an implant is involved).	FDA [9] CDC [10]
Bacteraemia	The presence of viable bacteria in the blood documented by a positive blood culture result	CDC [11]
Defined daily dose (DDD)	The assumed average maintenance dose per day for a drug used for its main indication in adults. For antimicrobial consumption in hospital, the indicator DDD/100 patients-days is generally used.	WHO [12]
Diabetic foot infection (DFI)	Foot wound infection in diabetic patients defined by the presence of at least two classic findings of inflammation or purulent secretions.	IDSA [13]
Hospital-acquired pneumonia (HAP)	Pneumonia acquired ≥ 48 hours after hospital admission.	IDSA [14]
Intra-abdominal infections (IAIs)	Infections that develop within the abdominal cavity, usually classified into uncomplicated and complicated.	WSES [15]
Multidrug-resistant organisms (MDRO)	Microorganisms, predominantly bacteria, that are resistant to one or more classes of antimicrobial agents.	CDC [16]
No infection/Colonisation	Absence of local or systemic signs and symptoms of infection, even in presence of bacterial isolation.
Sepsis	Life-threatening organ dysfunction caused by a dysregulated host response to infection.	Singer et al., 2016 [17]
Septic arthritis and/or Spinal infections	Septic arthritis: An acute inflammation involving one or more joints on an infectious basis confirmed by a positive culture of synovial fluid. Spinal infections: Include vertebral, discitis and spondylodiscitis.	Colston at Atkins, 2018 [18] EANM/ESNR/ESCMID [19]
Urinary tract infections (UTIs)	Infections involving any part of the urinary system. They include both lower (cystitis) and upper (pyelonephritis) UTIs and are classified into uncomplicated and complicated.	EAU [20]

Statistical analysis

Descriptive statistics were produced for all variables. Mean and standard deviation (SD) are presented for normally distributed variables, and median and interquartile range (IQR) for non-normally distributed variables, numbers, and percentages for categorical variables. Whenever relevant, 95% confidence intervals (95% CI) were calculated. Shapiro Wilk’s and Kolmogorov-Smirnov test, as well as visual methods, were applied to test for normality.

For comparison between the study periods, Student t test (Mann-Whitney test for skewed distributions) was used for quantitative variables (ANOVA or Kruskall-Wallis for > 2 groups respectively), and Pearson’s chi-squared test (Fisher exact test where appropriate) for categorical variables. In all cases, 2-tailed tests were used. P-value significance cut-off was 0.05.

Stata computer software version 15.0 (Stata Corporation, 4905 Lakeway Drive, College Station, Texas 77845, USA) was used for statistical analysis.

Between the 1st July 2018 and the 30th June 2019, among a total number of 689 patients admitted in the Vascular Surgery ward for at least 48 hours, 108 (15.67%) patients received at least one evaluation from the ID consultants, for a maximum of six different evaluations for a single patient. The median age was 71 (IQR 63–78) and 79 patients (73.15%) were males. The most prevalent underlying disease was of cardiovascular aetiology, followed by diabetes and metabolic comorbidities (Table 2).

Overall, 186 prescriptions were revised. The most prevalent infectious condition evaluated during the intervention period was ABSSSI and/or surgical site infection, accounting for 52 patients (48.15%), followed by HAP (15 patients, 13.89%) (Table 2).

Table 2

Characteristics of patients evaluated in the Vascular Surgery ward.
Variables	Overall (N = 108)
Age (y), median (IQR)	71 (63–78)
Gender (male), n (%)	79 (73.15)
Comorbidities
Cardiovascular, n (%)	102 (94.44)
Diabetes, n (%)	48 (44.44)
Haematologic, n (%)	5 (4.63)
HCV, n (%)	4 (3.70)
HIV, n (%)	1 (0.93)
Immunologic, n (%)	4 (3.70)
Metabolic, n (%)	59 (54.63)
Neurologic, n (%)	4 (3.70)
Oncologic, n (%)	3 (2.78)
Osteoarticular, n (%)	3 (2.78)
Respiratory, n (%)	15 (13.89)
Urologic, n (%)	17 (15.74)
Type of infection evaluated
ABSSSI and/or surgical site infection, n (%)	52 (48.15)
Bacteremia, n (%)	2 (1.85)
Diabetic foot infection, n (%)	10 (9.26)
Hospital-acquired pneumonia, n (%)	15 (13.89)
Intra-abdominal infection, n (%)	7 (6.48)
No infection/colonization, n (%)	13 (12.04)
Sepsis, n (%)	1 (0.93)
Septic arthritis and/or osteomyelitis, n (%)	6 (5.55)
Urinary tract infection, n (%)	2 (1.85)

Regarding the outcomes of the prescriptions’ revisions, those bringing to a de-escalation of an ongoing antimicrobial therapy were the most prevalent (39 revisions, 20.97%), followed by decisions to start an antimicrobial therapy (34 revisions, 18.28%) and to escalate (32 revisions, 17.20%). Antimicrobial treatments were left unmodified in 31 revisions (16.67%) and were discontinued or not recommended in 22 and 16 revisions, respectively (11.83% and 8.60%). Finally, antimicrobial choices and dosages were modified in 9 and 3 revisions (4.84% and 1.61%, respectively) (Fig. 1). As a result, antimicrobials were discontinued, not prescribed or de-escalated in 77 revisions (41.4%).

Occurrence of MRDO isolates.

Comparing Period A and Period B, we reported a statistically significant decrease of isolates of carbapenem-resistant Pseudomonas aeruginosa (p-value 0.003, Table 3). Occurrence of ESBL-producing enteric Gram-negative bacteria also decreased but not significantly. Remarkably, during the intervention period no Clostridioides difficile infections were reported.

Table 3 Summary of the study outcomes.

	Period A (1^st July 2017 – 30^th June 2018)	Period B (1^st July 2018 – 30^thJune 2019)	p-value
Occurrence of MDRO infections
Carbapenem-resistant Pseudomonas aeruginosa, n	7	1	<0.01
Clostridioides difficile, n	2	0	0.10
ESBL-producing enteric Gram-negative bacteria, n	18	14	0.59
Length of in-hospital stay, mean	9.46	9.8	0.60
All-cause in-hospital mortality, n (%)	19 (2.68)	15 (2.15)	0.50
Antibiotic consumption
Carbapenems, DDDs*100 PDs, mean	4.53	1.51	0.01
Daptomycin, DDDs*100 PDs, mean	2.64	0.05	<0.01
Clindamycin, DDDs*100 PDs, mean	0.33	3.34	<0.01
Antibiotic costs, euros	54,876.44	21,777.26	0.03

Abbreviations: ESBL: extended-spectrum beta-lactamase.

Secondary outcomes.

No statistically significant changes before and after the implementation of the ASP in the Vascular Surgery ward were observed in terms of length of stay and all-cause in-hospital mortality (Table 3).

During the 12-month period following the start of the ASP, we noticed an improvement in the antimicrobial prescription appropriateness. More precisely, our intervention was particularly effective in reducing the administration of carbapenems, daptomycin and linezolid. The monthly mean DDDs*100 PDs of carbapenems decreased from 4.53 to 1.51 (p-value 0.01) and daptomycin DDDs*100 PDs from 2.64 to 0.05 (p-value <0.01, see Table 3). Linezolid DDDs*100 PDs also diminished from 0.49 to 0.26 (p-value 0.43, data not shown).

Glycopeptides, specifically vancomycin, were used as anti-MRSA agents in place of daptomycin, so we noticed a non-statistically significant increase of administered DDDs*100 PDs in concomitance with our intervention (p-value 0.14, data not shown). Similarly, consumptions of both trimethoprim/sulfametoxazole (TMP/SMX) and fluoroquinolones increased non significantly: TMP/SMX DDDs increased from 3,953 to 7,191 (p-value 0.0584, data not shown) whereas fluoroquinolones DDDs increased from 9,1893 to 13,408 (p-value 0.2553, data not shown). Oral fosfomycin was introduced in the clinical practice of the Vascular Surgery ward to treat uncomplicated lower urinary tract infections, in place of beta-lactams. In particular, DDDs*100 PDs of fosfomycin increased from 0 to 0.65 (p-value 0.0258, data not shown).

Penicillins had a non-significant increase of administration, from 33,92 to 36.91 DDDs*100 PDs (p-value 0.9372, data not shown), as third generation cephalosporins, which moved from 3,52 to 4,29 DDDs*100 PDs (p-value 0.6649, data not shown). As regards antifungals, we noticed a non-significant decrease of DDDs*100 PDs from 0.23 to 0.15 (p-value 0.96, data not shown).

During the intervention period, a significant reduction in antimicrobial costs was observed. In particular, the total cost of antimicrobial drugs prescribed in the Vascular Surgery ward after the start of the ASP was equal to 21.777,26 €, with a net difference of 33.099,18 € (60,31%; p value 0.03, see Table 3) compared to the previous 12 months (54.876,44 €).

After performing a 12-month period of antimicrobial stewardship intervention in the Vascular Surgery ward of our hospital, we have certainly achieved some positive results, both from a microbiological and economic perspective. On the one hand, in Period B we reported a minor incidence rate of carbapenem-resistant Pseudomonas aeruginosa isolates and the absence of infections caused by Clostridioides difficile. On the other hand, we also observed a significant reduction in the consumption of some broad-spectrum and expensive antimicrobial drugs compared to Period A, with no adverse influence on LOS and mortality. These findings are in line with the avowed concept of the utility of ASPs in minimizing antimicrobial resistance and Clostridioides difficile diarrhoea [21]. Hence, since the strong correlation between the multidrug-resistant Pseudomonas aeruginosa incidence rate and broad-spectrum antimicrobial consumption, a substantial decline in the prescription of these drugs, which is accomplished by ASPs, might effectively control the occurrence of such resistant microorganism [22].

Regarding antimicrobial costs, a recent narrative review thoroughly discussed the most recent evidence on the positive consequences of ASPs for healthcare systems, concluding that, despite ASPs would be cost-effectiveness, the majority of the available studies do not deal with cost–utility analyses, rendering an unambiguous evaluation difficult [23]. In our particular case, though, we have to consider that the model of stewardship intervention we implemented has not required any further costs. In fact, our ASP can be classified as a “handshake stewardship” strategy, as it is centered on the in-person approach to feedback and thus it is based on the commitment of the two ID consultants in terms of number of hours spent weekly in the surgical ward [24].

Along with considering the achieved results as a prompt to reflect on the magnitude and apparent simplicity of ASPs, the strength of our work resides in laying the groundwork for a team effort. In fact, we believe that a successful ASP cannot be indeed achieved without the support and joint collaborative effort between different hospital units; this is favoured by the direct communication promoted by a model of stewardship as ours, which includes some of the core elements required for an ASP, namely multidisciplinary teamwork, accountability, enabling actions and education [25].

It could be argued that, despite our work has been conceived as a quality-improvement study, no changes have been observed in terms of LOS and all-cause in-hospital mortality, which are part of the so-called outcome measures. However, it has been recognised that these kinds of indicators may be misleading in evaluating the quality of hospital care; instead, clinical process measures, such as the formerly mentioned decline in incidence of healthcare-associated infections, must be preferred, as they are a direct measure of performance based on adherence to established clinical standards [26]. In fact, in our study a solid effect on these measures has been reported, so we can assert with good reason that an improvement in the quality of care of the Vascular Surgery ward has been obtained thanks to the implementation of the ASP.

We should not neglect some of the limitations of our study. Firstly, the Pharmacy Unit of our Hospital lacks a computerized drugs prescription and administration system. For this reason, the data of antimicrobial consumption were inferred from the amount dispensed from the Pharmacy Unit to the Vascular Surgery ward and thus may not accurately reflect the real usage trend.

Secondly, we did not analyse the extent of antimicrobial prescriptions following the patients’ discharge. These data are a significant marker for antimicrobial exposure and may impact both colonization and infections caused by MDRO.

In conclusion, the implementation of a 12-month antimicrobial stewardship program brought significant clinical and economic results in the Vascular Surgery ward of our hospital, highlighting the benefits of a multidisciplinary teamwork and the importance of the commitment of each actor involved, both medical and non-medical.

We hope to further extend this model of antimicrobial stewardship program to a hospital level, possibly integrating it with modern technologies intended to help the prescription activity and the collection of data for additional evaluations.

ABSSSI: acute bacterial skin and skin structure infection

ADs: antimicrobial drugs

AMR: antimicrobial resistance

ASP: antimicrobial stewardship programs

CI: confidence interval

DDD: defined daily dose

DFI: diabetic foot infection

EANM: European Association of Nuclear Medicine

ESBL: extended spectrum beta-lactamase

ESCMID: European Society of Clinical Microbiology and Infectious Diseases

ESNR: European Society of Neuroradiology

FDA: Food and Drugs Administration

CDC: Centers for Disease Control and prevention

HAP: hospital-acquired pneumonia

HCV: hepatitis C virus

HIV. human immunodeficiency virus

IAI: intra-abdominal infection

ID: infectious diseases

IDSA: Infectious Diseases Society of America

IQR: interquartile range

LOS: length of stay

MRSA: methicillin-resistant Staphylococcus aureus

MDRO: multidrug-resistant organism

PAD: peripheral artery disease

PPE: personal protection equipment

SD: standard deviation

SSI: surgical site infection

TMP/SMX: trimethoprim/sulfametoxazole

UTI: urinary tract infection

WHO: World Health Organization

WSES: World Society of Emergency Surgery

Ethics approval and consent to participate

Our research was conducted according to the principles outlined in the Declaration of Helsinki. The experimental protocol was approved by the Institutional Review Board (Comitato Etico di Pavia, n. prot. 20190069514). Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Funding.

No funding was received for conducting this study or to assist with the preparation of this manuscript.

Authors’ contribution

M.V., M.C. and P.S. conceived the presented idea, analysed the results, and wrote the final manuscript. L.N.M., A.S., J.L., S.B. and F.R. encouraged to investigate and supervised the findings of this work. P.M., S.C., A.M., C.M., M.C. and L.S. contributed to the design and implementation of the research. E.M.M. and R.B. supervised the project. L.N.M., A.S. and R.B. contributed to the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgements

Not applicable.

Talebi Bezmin Abadi A, Rizvanov AA, Haertlé T, Blatt NL. ‘World Health Organization Report: Current crisis of antibiotic resistance’, BioNanoScience, vol. 9, no. 4, pp. 778–788, Dec. 2019, doi: 10.1007/s12668-019-00658-4.
Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M, Wolkewitz M. ‘Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study’. Lancet Infect Dis. Jan. 2011;11(1):30–8. doi:10.1016/S1473-3099(10)70258-9.
Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, Diaz E, Fernández-Barat L, Li Bassi GL, Ferrer M, ‘Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms’, J Infect, vol. 70, no. 3, pp. 213–222, Mar. 2015, doi: 10.1016/j.jinf.2014.10.004.
Tammer I, Geginat G, Lange S, Kropf S, Lodes U, Schlüter D, Lippert H, Meyer F, ‘Antibiotic consumption and the development of antibiotic resistance in surgical units’, Zentralbl Chir, vol. 141, no. 01, pp. 53–61, Feb. 2016, doi: 10.1055/s-0033-1351087.
Manuel Vázquez A, Balibrea JM, Ramia JM, ‘Antimicrobial stewardship programs and surgery: What is our role?’, Cir Esp, vol. 97, no. 4, pp. 187–189, Apr. 2019, doi: 10.1016/j.ciresp.2018.07.008.
Leeds IL, Fabrizio A, Cosgrove SE, Wick EC. ‘Treating wisely: The surgeon’s role in antibiotic stewardship’. Ann Surg. 2017;265(5):871–3. doi:10.1097/SLA.0000000000002034.
Zamani N, Sharath SE, Barshes NR, Braun JD, Kougias P, ‘Long-term outcomes of lower extremity graft preservation using antibiotic beads in patients with early deep wound infections after major arterial reconstructions’, J Vasc Surg, vol. 71, no. 4, pp. 1315–1321, Apr. 2020, doi: 10.1016/j.jvs.2019.06.192.
Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. ‘SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process’. BMJ Qual Saf. 2016;25(12):986–92. doi:10.1136/bmjqs-2015-004411.
U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research. ‘Acute Bacterial Skin and Skin Structure Infections: Developing drugs for treatment’, p. 18, 2013. https://www.fda.gov/files/drugs/published/Acute-Bacterial-Skin-and-Skin-Structure-Infections---Developing-Drugs-for-Treatment.pdf. Accessed 03 Apr 2022.
Borchardt RA, Tzizik D, ‘Update on surgical site infections: The new CDC guidelines’, JAAPA, vol. 31, no. 4, pp. 52–54 2018, doi: 10.1097/01.JAA.0000531052.82007.42.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM, ‘CDC definitions for nosocomial infections, 1988’, Am J Infect Control, vol. 16, no. 3, pp. 128–140, Jun. 1988, doi: 10.1016/0196-6553(88)90053-3.
WHO Collaborating Centre for Drug Statistics Methodology. ‘Guidelines for ATC classification and DDD assignment 2022’, p. 250, 2022. https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/. Accessed 03 Apr 2022.
Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E. Infectious Diseases Society of America, ‘2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and treatment of Diabetic Foot Infections’. Clin Infect Dis. Jun. 2012;54(12):e132–73. doi:10.1093/cid/cis346.
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. ‘Management of adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society’. Clin Infect Dis. Sep. 2016;63(5):e61–111. doi:10.1093/cid/ciw353.
Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, Ansaloni L, Bala M, Balogh ZJ, Beltrán MA, Ben-Ishay O, Biffl WL, Birindelli A, Cainzos MA, Catalini G, Ceresoli M, Che Jusoh A, Chiara O, Coccolini F, Coimbra R, Cortese F, Demetrashvili Z, Di Saverio S, Diaz JJ, Egiev VN, Ferrada P, Fraga GP, Ghnnam WM, Lee JG, Gomes CA, Hecker A, Herzog T, Kim JI, Inaba K, Isik A, Karamarkovic A, Kashuk J, Khokha V, Kirkpatrick AW, Kluger Y, Koike K, Kong VY, Leppaniemi A, Machain GM, Maier RV, Marwah S, McFarlane ME, Montori G, Moore EE, Negoi I, Olaoye I, Omari AH, Ordonez CA, Pereira BM, Pereira Júnior GA, Pupelis G, Reis T, Sakakhushev B, Sato N, Segovia Lohse HA, Shelat VG, Søreide K, Uhl W, Ulrych J, Van Goor H, Velmahos GC, Yuan KC, Wani I, Weber DG, Zachariah SK, Catena F. ‘The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections’, World J Emerg Surg, 12, 1, p. 29, Jul. 2017, doi:10.1186/s13017-017-0141-6.
Siegel JD, Rhinehart E, Jackson M, Chiarello L. Healthcare Infection Control Practices Advisory Committee, ‘Management of Multidrug-Resistant Organisms In healthcare settings, 2006’, Am J Infect Control, vol. 35, no. 10 Suppl 2, pp. 165 – 93, Dec 2007, doi: 10.1016/j.ajic.2007.10.006.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. ‘The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)’. JAMA. Feb. 2016;315(8):801–10. doi:10.1001/jama.2016.0287.
Colston J, Atkins B. ‘Bone and joint infection’. Clin Med (Lond). Apr. 2018;18(2):150. doi:10.7861/clinmedicine.18-2-150.
Lazzeri E, Bozzao A, Cataldo MA, Petrosillo N, Manfrè L, Trampuz A, Signore A, Muto M, ‘Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults’, Eur J Nucl Med Mol Imaging, vol. 46, no. 12, pp. 2464–2487, Nov. 2019, doi: 10.1007/s00259-019-04393-6.
Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Köves B, chubert S, Pilatz A, Veeratterapillay R, Wagenlehner F. ‘EAU Guidelines on Urological Infections’, 2022. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2022.pdf. Accessed 03 Apr 2022.
Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, Holmes A, Ramsay C, Taylor E, Wilcox M, Wiffen P. ‘Interventions to improve antibiotic prescribing practices for hospital inpatients’, Cochrane Database Syst Rev, 2017, 2, Feb. 2017, doi:10.1002/14651858.CD003543.pub4.
Liu L, Liu B, Li Y, Zhang W, ‘Successful control of resistance in Pseudomonas aeruginosa using antibiotic stewardship and infection control programs at a Chinese university hospital: a 6-year prospective study’, Infect Drug Resist, vol. Volume 11, pp. 637–646, May 2018, doi: 10.2147/IDR.S163853.
Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. ‘Antimicrobial stewardship at a large tertiary care academic medical center: Cost analysis before, during, and after a 7-year program’. Infect Control Hosp Epidemiol. 2012;33(4):338–45. doi:10.1086/664909.
Hurst AL, Child J, Pearce K, Palmer C, Todd JK, Parker SK. ‘Handshake Stewardship: A Highly Effective Rounding-based Antimicrobial Optimization Service’. Pediatr Infect Dis J. 2016;35(10):1104–10. doi:10.1097/INF.0000000000001245.
Centers for Disease Control and Prevention. ‘Core Elements of Hospital Antibiotic Stewardship Programs’, Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.
Lilford R, Mohammed MA, Spiegelhalter D, Thomson R, ‘Use and misuse of process and outcome data in managing performance of acute medical care: avoiding institutional stigma’, Lancet, vol. 363, no. 9415, pp. 1147–1154, Apr. 2004, doi: 10.1016/S0140-6736(04)15901-1.

No competing interests reported.

Download PDF

Journal Publication

published 06 Mar, 2023

Read the published version in BMC Infectious Diseases →

Editorial decision: Major revision
05 Jan, 2023
Reviews received at journal
22 Dec, 2022
Reviewers agreed at journal
09 Dec, 2022
Reviewers invited by journal
06 Dec, 2022
Editor assigned by journal
22 Nov, 2022
Editor invited by journal
22 Nov, 2022
Submission checks completed at journal
22 Nov, 2022
First submitted to journal
10 Nov, 2022

You are reading this latest preprint version

Implementation of an Antimicrobial Stewardship Program in the Vascular Surgery Ward of a university tertiary care hospital in Pavia, Northern Italy

Status:

Journal Publication

Version 3

Abstract

Figures

Background

Methods

Study design, settings, and duration

Intervention

Measures

Definitions

Statistical analysis

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 3